Search Results - "Tse, Archie N."

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia by Yue, Zenglian, Pan, Chaohsuan, Wang, Siyuan, N. Tse, Archie, Sheng, Yucheng

“…Purpose This study aimed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of ivosidenib in Chinese patients with relapsed or refractory acute…”
Get full text

Targeting Checkpoint Kinase 1 in Cancer Therapeutics by TSE, Archie N, CARVAJAL, Richard, SCHWARTZ, Gary K

“…Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Our knowledge of the biochemical nature of…”
Get full text

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies by Zabludoff, Sonya D, Deng, Chun, Grondine, Michael R, Sheehy, Adam M, Ashwell, Susan, Caleb, Benjamin L, Green, Stephen, Haye, Heather R, Horn, Candice L, Janetka, James W, Liu, Dongfang, Mouchet, Elizabeth, Ready, Shannon, Rosenthal, Judith L, Queva, Christophe, Schwartz, Gary K, Taylor, Karen J, Tse, Archie N, Walker, Graeme E, White, Anne M

“…Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor…”
Get full text

Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302 by Sheng, Yucheng, Teng, Shu‐wen, Wang, Jingru, Wang, Hao, Tse, Archie N.

“…Overall survival is vital for approving new anticancer drugs but is often impractical for early‐phase studies. The tumor growth inhibition‐overall survival…”
Get full text

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780 by Nair, Jayasree S, Ho, Alan L, Tse, Archie N, Coward, Jesse, Cheema, Haider, Ambrosini, Grazia, Keen, Nicholas, Schwartz, Gary K

“…The phenotypic change characteristic of Aurora B inhibition is the induction of polyploidy. Utilizing specific siRNA duplexes and a selective small molecule…”
Get full text

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo by TSE, Archie N, RENDAHL, Katherine G, HIBNER, Barbara, GESNER, Thomas G, SCHWARTZ, Gary K, SHEIKH, Tahir, CHEEMA, Haider, AARDALEN, Kim, EMBRY, Millicent, MA, Sylvia, MOLER, Edward J, ZHI JIE NI, LOPES DE MENEZES, Daniel E

“…Purpose: Chk1 kinase is a critical regulator of both S and G 2 -M phase cell cycle checkpoints in response to DNA damage. This study aimed to evaluate the…”
Get full text

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors by TSE, Archie N, KLIMSTRA, David S, KI CHUNG, MAKI, Robert, LEFKOWITZ, Robert, BROWN, Karen, MANOVA-TODOROVA, Katia, NIAN WU, EGORIN, Merrill J, KELSEN, David, SCHWARTZ, Gary K, GONEN, Mithat, SHAH, Manish, SHEIKH, Tahir, SIKORSKI, Rachel, CARVAJAL, Richard, MUI, Janet, TIPIAN, Caroll, O'REILLY, Eileen

“…Purpose: Both heat shock protein 90 (Hsp90) and checkpoint kinase 1 (Chk1) have emerged as novel therapeutic targets. We conducted a phase I study of…”
Get full text

Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies by Wang, Kun, Pan, Chaohsuan, Xu, Fengyan, Tse, Archie N, Sheng, Yucheng

“…The aim of this study was to develop a population pharmacokinetics model for sugemalimab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1),…”
Get full text

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study by Bishnoi, Sarwan, Kotasek, Dusan, Aghmesheh, Morteza, Yau, Thomas, Cosman, Rasha, Prawira, Amy, Moore, Maggie, Chan, Stephen L., Mant, Andrew, Eek, Richard, Zielinski, Robert, Su, Rila, Pan, Zhaoxuan, Ma, Yiding, Li, Fei, Li, Peiqi, Tse, Archie N.

“…Background This study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1…”
Get full text

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer by Day, Daphne, Park, John J., Coward, Jermaine, Markman, Ben, Lemech, Charlotte, Kuo, James C., Prawira, Amy, Brown, Michael P., Bishnoi, Sarwan, Kotasek, Dusan, Strother, R. Matthew, Cosman, Rasha, Su, Rila, Ma, Yiding, Yue, Zenglian, Hu, Hui-han, Wu, Rachel, Li, Peiqi, Tse, Archie N.

“…Background We assessed nofazinlimab, an anti-PD-1 antibody, in solid tumors and combined with regorafenib in metastatic colorectal cancer (mCRC). Methods This…”
Get full text

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma by Gong, Jifang, Guo, Ye, Zhang, Yanqiao, Ba, Yi, Chen, Tong, Li, Wei, Zhou, Caicun, Wang, Mengzhao, Yang, Haiyan, Zhou, Yuhong, Cai, Qiqing, Wang, Ziping, Huang, Gang, Zhang, Wei, Su, Rila, Cai, Zhongheng, Yue, Zenglian, Dou, Jinzhou, Li, Peiqi, Wu, Rachel, Tse, Archie N., Shen, Lin

“…Background Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies has demonstrated efficacy in multiple tumor types. Nofazinlimab is a…”
Get full text

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer by Ciprotti, Marika, Tebbutt, Niall C, Lee, Fook-Thean, Lee, Sze-Ting, Gan, Hui K, McKee, David C, O'Keefe, Graeme J, Gong, Sylvia J, Chong, Geoffrey, Hopkins, Wendie, Chappell, Bridget, Scott, Fiona E, Brechbiel, Martin W, Tse, Archie N, Jansen, Mendel, Matsumura, Manabu, Kotsuma, Masakatsu, Watanabe, Rira, Venhaus, Ralph, Beckman, Robert A, Greenberg, Jonathan, Scott, Andrew M

“…CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to…”
Get full text

Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe by TSE, Archie N, SCHWARTZ, Gary K

“…UCN-01 is a potent inhibitor of the S- and G2-M-phase cell cycle checkpoints by targeting chk1 and possibly chk2 kinases. It has been shown in some, but not…”
Get full text

phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies by Tse, Archie N, Wu, Nian, Patel, Dina, Haviland, Dana, Kemeny, Nancy

“…Purpose To determine the maximum tolerated dose and duration of hepatic arterial infusion (HAI) gemcitabine in patients with unresectable hepatic metastases…”
Get full text

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1 by Tse, Archie N, Sheikh, Tahir N, Alan, Ho, Chou, Ting-Chao, Schwartz, Gary K

“…The G(2)/M cell cycle checkpoint is regulated by a multitude of signaling pathways after genotoxic stress. Herein, we report that treatment with the 90-kDa…”
Get more information

Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC) by Shen, Lin, Guo, Ye, Zhang, Yanqiao, Li, Wei, Gong, Jifang, Li, Qun, Ma, Zhigang, Wang, Nanya, Su, Rila, Cai, Zhongheng, Guo, Rong, Li, Peiqi, Tse, Archie N.

“…e16191 Background: CS1003 is a novel humanized, recombinant IgG4 anti-PD-1 monoclonal antibody. LEN, a multi-kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα,…”
Get full text

Abstract LBA008: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies by Li, Fu, Li, Yongwang, Zhang, Lan, Zhang, Clarence K., Hu, Hui-Han A., Zhang, Juan, Pan, Ying, Jung, Jinwon, Lee, Sang Hoon, Ryu, Hyun-Min, Park, Yun-Hee, Yu, Haixiang, Tse, Archie N.

“…ROR1 (receptor tyrosine kinase-like orphan receptor 1) is an oncofetal protein prevalently expressed in a variety of hematological and solid malignancies but…”
Get full text

Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST by Goldmacher, Gregory V., Khilnani, Anuradha D., Andtbacka, Robert H. I., Luke, Jason J., Hodi, F. Stephen, Marabelle, Aurelien, Harrington, Kevin Joseph, Perrone, Andrea Marie, Tse, Archie N., Madoff, David C., Schwartz, Lawrence Howard

“…Abstract only 3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs…”
Get full text

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors by Patnaik, Amita, Eisenberg, Peter D., Sachdev, Jasgit C., Weise, Amy M., Tse, Archie N., Hutchinson, Marguerite, Aromin, Ireene, West, Brian, Tong, Sandra, Ribas, Antoni, Hu-Lieskovan, Siwen

“…Abstract only…”
Get full text

Abstract 2870: Dose selection investigations and combination strategies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate by Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Lichtlen, Peter, Liu, Linlin, Teng, Shu-wen, Zhang, Lan, Pan, ChaoHsuan, Li, Peiqi, Tietz, Julia, Brock, Matthias, Simonim, Alexandre, Hess, Christian, Weinert, Christopher, Johansson, Maria, Chatterjeee, Bithi, Bassler, Nicole, Kirk, Niels, Mendes, Catia, Heiz, Robin, Flueckiger, Naomi, Diem, Dania, Mahler, Dana, Wickihalder, Belinda, Muntwiler, Simone, Wagen, Sandro, vom Baur, Elmar, Tse, Archie N., Urech, David

“…Antagonistic molecules targeting the PD-1/PD-L1 axis have shown excellent activity in the clinic. However, the majority of patients do not respond to the…”
Get full text